[
  {
    "ts": null,
    "headline": "Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination",
    "summary": "Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination",
    "url": "https://finnhub.io/api/news?id=9f75a31a5caf23f9f9434f7807836e82fa46100c7b12d7aa59f0715430d5117f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744295724,
      "headline": "Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination",
      "id": 133861205,
      "image": "",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=9f75a31a5caf23f9f9434f7807836e82fa46100c7b12d7aa59f0715430d5117f"
    }
  },
  {
    "ts": null,
    "headline": "Harbor Capital Factor U.S. Large Cap ETF Q4 2024 Commentary",
    "summary": "During the fourth quarter, Harbor Human Capital Factor US Large Cap ETF returned 2.72%, (at NAV) slightly underperforming CIBC Human Capital Index, which returned 2.80%.",
    "url": "https://finnhub.io/api/news?id=d513c95f6496914a3dbc2eb9f9d0b1f3e3ebba81993138c72ceab7f04b45ca60",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744283580,
      "headline": "Harbor Capital Factor U.S. Large Cap ETF Q4 2024 Commentary",
      "id": 133847889,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2170834274/image_2170834274.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "During the fourth quarter, Harbor Human Capital Factor US Large Cap ETF returned 2.72%, (at NAV) slightly underperforming CIBC Human Capital Index, which returned 2.80%.",
      "url": "https://finnhub.io/api/news?id=d513c95f6496914a3dbc2eb9f9d0b1f3e3ebba81993138c72ceab7f04b45ca60"
    }
  },
  {
    "ts": null,
    "headline": "Dow's 965-point fall led by losses in shares of Nike, Walt Disney",
    "summary": "Dow's 965-point fall led by losses in shares of Nike, Walt Disney",
    "url": "https://finnhub.io/api/news?id=ed1114ab348ff3cb99d44dd0876c0bb61ea6436575b3bf4cc9de9e75ba4b58d3",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744282140,
      "headline": "Dow's 965-point fall led by losses in shares of Nike, Walt Disney",
      "id": 133846388,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Dow's 965-point fall led by losses in shares of Nike, Walt Disney",
      "url": "https://finnhub.io/api/news?id=ed1114ab348ff3cb99d44dd0876c0bb61ea6436575b3bf4cc9de9e75ba4b58d3"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb",
    "summary": "Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb are included in this Analyst Blog.",
    "url": "https://finnhub.io/api/news?id=478671d2a2e66f3ca5c76125a46ae18e31b64d6095f57cad00caaab46848073f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744275600,
      "headline": "The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb",
      "id": 133844319,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb are included in this Analyst Blog.",
      "url": "https://finnhub.io/api/news?id=478671d2a2e66f3ca5c76125a46ae18e31b64d6095f57cad00caaab46848073f"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Is Getting Into the Obesity Drug Business. Buy the Stock Before It Becomes the  Next Winner.",
    "summary": "Despite resilient demand, healthcare has taken a hit along with the rest of the market. This Big Pharma could boost profits significantly in the years ahead.",
    "url": "https://finnhub.io/api/news?id=8ae55e90fd7e44bba5658142350eeb92c65ef647fa12b1452fa5207c3ff80125",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744261200,
      "headline": "Amgen Is Getting Into the Obesity Drug Business. Buy the Stock Before It Becomes the  Next Winner.",
      "id": 133844320,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Despite resilient demand, healthcare has taken a hit along with the rest of the market. This Big Pharma could boost profits significantly in the years ahead.",
      "url": "https://finnhub.io/api/news?id=8ae55e90fd7e44bba5658142350eeb92c65ef647fa12b1452fa5207c3ff80125"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Is Getting Into the Obesity Drug Business. The Stock Could Become the  Next Winner.",
    "summary": "Amgen Is Getting Into the Obesity Drug Business. The Stock Could Become the  Next Winner.",
    "url": "https://finnhub.io/api/news?id=4455ef573a8f8eb179868890532b7baa71802c9f375950b0ee9ea5ad9ec5d55b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744246800,
      "headline": "Amgen Is Getting Into the Obesity Drug Business. The Stock Could Become the  Next Winner.",
      "id": 134148451,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Amgen Is Getting Into the Obesity Drug Business. The Stock Could Become the  Next Winner.",
      "url": "https://finnhub.io/api/news?id=4455ef573a8f8eb179868890532b7baa71802c9f375950b0ee9ea5ad9ec5d55b"
    }
  }
]